Wed, Nov 13, 6:13 PM (127 days ago)
Vivos Inc. (RDGL) reported its Q3 2024 financial results, showing a revenue of $5,000, down from $7,000 in Q3 2023, and a net loss of $825,263, compared to a loss of $667,690 the previous year. For the nine months ended September 30, 2024, total revenue was $23,000 against $19,500 in 2023, with a net loss of $1,887,260 compared to $1,818,534 in the prior year. Operating expenses increased to $844,226 in Q3 2024, driven by higher professional fees and general administrative costs, while R&D expenses decreased as previous studies concluded. Cash flow from operations showed a significant increase in outflows, totaling $1,213,127 for the nine months, reflecting ongoing operational challenges. As of September 30, 2024, Vivos held $1,218,160 in cash, down from $1,592,287 at the end of 2023, indicating liquidity constraints. The company relies on ongoing Regulation A+ offerings to fund operations, requiring approximately $5 million annually. Future funding and FDA approvals are critical for sustaining operations and expanding its product line, particularly in veterinary oncology. The company's ability to continue as a going concern remains uncertain without additional capital.